How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Circadian Rhythm Sleep Disorders Drug Market
- By Drug Class: Melatonin Receptor Agonists, Stimulants, Hypnotics and Sedatives, Chronobiotics, Antidepressants
- By Indication: Delayed Sleep Phase Disorder (DSPD), Advanced Sleep Phase Disorder (ASPD), Non-24-Hour Sleep-Wake Disorder, Irregular Sleep-Wake Rhythm Disorder, Shift Work Sleep Disorder
- By Route of Administration: Oral Tablets, Oral Capsules, Sublingual Tablets, Injectables, Transdermal Patches
- By End User: Hospitals, Specialty Clinics, Sleep Disorder Centers, Home Care Settings, Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Melatonin Receptor Agonists leads By Drug Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Circadian Rhythm Sleep Disorders Drug Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Hoffmann-La Roche Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Takeda Pharmaceutical Company Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Jazz Pharmaceuticals plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Eisai Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sunovion Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Neurim Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vanda Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mylan N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Boehringer Ingelheim GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Otsuka Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →AbbVie Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Melatonin Receptor Agonists55.6
- Stimulants11.7
- Hypnotics and Sedatives9.6
- Chronobiotics7.3
- Antidepressants15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Hoffmann-La Roche Ltd20.9
- Takeda Pharmaceutical Company Limited17.6
- Sanofi S.A.4.8
- Bayer AG11.8
- Jazz Pharmaceuticals plc8.9
- Eisai Co. Ltd.8.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.9
- Europe21.4
- Asia Pacific23.2
- Latin America13.3
- Middle East and Africa10.1
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Hoffmann-La Roche Ltd | 82 | 97 | 87 | 77 | 84 | 98 | 88 |
| Takeda Pharmaceutical Company Limited | 82 | 79 | 79 | 73 | 69 | 74 | 76 |
| Sanofi S.A. | 70 | 72 | 87 | 82 | 63 | 86 | 77 |
| Bayer AG | 63 | 59 | 81 | 82 | 65 | 68 | 70 |
| Jazz Pharmaceuticals plc | 63 | 53 | 75 | 73 | 72 | 54 | 65 |
| Eisai Co. Ltd. | 57 | 66 | 65 | 53 | 56 | 70 | 61 |
| Sunovion Pharmaceuticals Inc. | 43 | 65 | 60 | 57 | 51 | 46 | 54 |
| Neurim Pharmaceuticals Ltd. | 38 | 40 | 60 | 51 | 39 | 41 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Hoffmann-La Roche Ltd
- Takeda Pharmaceutical Company Limited
- Sanofi S.A.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Hoffmann-La Roche Ltd | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Takeda Pharmaceutical Company Limited | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Sanofi S.A. | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Bayer AG | − | ◐ | ◐ | ◐ | ✓ | ✓ |
| Jazz Pharmaceuticals plc | ◐ | − | ◐ | ✓ | ◐ | ◐ |
| Eisai Co. Ltd. | − | ◐ | ◐ | − | − | ✓ |
| Sunovion Pharmaceuticals Inc. | − | − | ◐ | − | − | − |
| Neurim Pharmaceuticals Ltd. | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger3
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Drug Class in North America, then scale across Circadian Rhythm Sleep Disorders Drug Market — a $601M beachhead inside a $10.0B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Melatonin Receptor Agonists
Best fit — highest urgency & budget in Drug Class.
Stimulants
Strong fit — clear ROI and a fast path to value.
Hypnotics and Sedatives
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Drug Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Circadian Rhythm Sleep Disorders Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Circadian Rhythm Sleep Disorders Drug Market is a durable-growth opportunity — $4.10B by 2033, compounding at 8.1%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.1% CAGR
Demand compounds through 2033, outpacing GDP across Drug Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Class moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Circadian Rhythm Sleep Disorders Drug Market — a $5.17B market by 2033. Plan: grow share from 9.2% to 18.4%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.2% | 18.4% | On track |
| Revenue | $468M | $951M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 36.6% | 44.7% | On track |
| Customer retention | 90.7% | 92.8% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Drug Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $124M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Drug Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Circadian Rhythm Sleep Disorders Drug Market conversation — a $10.4B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Class
Goal Grow share in Drug Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Circadian Rhythm Sleep Disorders Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Circadian Rhythm Sleep Disorders Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Circadian Optics Light Therapy Lamp Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportCiprofol Injection Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportCiprofloxacin Lactate Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportCiprofloxacin Lactate and Sodium Chloride Injection Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCiprofloxacin Hydrochloride Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportCiprofloxacin Hydrochloride API Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportCiprofloxacin Eye Drops Market
Market size, share, segmentation and regional forecast.
$366M market · 2025 base year
View reportCiprofibrate Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCipepofol Injection Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportCinnarizine Market
Market size, share, segmentation and regional forecast.
$817M market · 2025 base year
View reportCinnarizine API Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCinitapride Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy